icon-folder.gif   Conference Reports for NATAP  
  64rd Annual Meeting of the
American Association for the
Study of Liver Diseases
Washington, DC Nov 1-5 2013
Back grey_arrow_rt.gif
Interferon-free Regimen Containing Setrobuvir in Combination with Ritonavir-boosted Danoprevir and Ribavirin with or without Mericitabine in HCV Genotype 1 Treatment-naive Patients: Interim Results from the ANNAPURNA Study
  Reported by Jules Levin
AASLD 2013 Nov 1-4 Wash DC
D.M. Jensen,1 M. Brunda,2 R. Elston,3 E.J. Gane,4 J. George,5 K. Glavini,3 J.M. Hammond,6 S. Le Pogam,2 I. Najera,2 S. Passe,2 A. Piekarska,7 I. Rodriguez,2 S. Zeuzem,8 T. Chu;2 on behalf of the ANNAPURNA study investigators
1University of Chicago Medicine, Chicago, IL, USA; 2Hoffmann-La Roche Inc, Nutley, NJ, USA; 3Roche Products Ltd, Welwyn, United Kingdom; 4Auckland Clinical Studies, Grafton, New Zealand; 5Storr Liver Unit, Westmead Hospital and University of Sydney, Westmead, NSW, Australia; 6F. Hoffmann-La Roche Ltd, Basel, Switzerland; 7Department of Infectious Diseases and Hepatology, Medical University of Lodz, Lodz, Poland; 8Medizinische Klinik I, Johann-Wolfgang-Goethe University Hospital, Frankfurt, Germany